全文获取类型
收费全文 | 37221篇 |
免费 | 3910篇 |
国内免费 | 1011篇 |
专业分类
耳鼻咽喉 | 1208篇 |
儿科学 | 1025篇 |
妇产科学 | 378篇 |
基础医学 | 6743篇 |
口腔科学 | 1427篇 |
临床医学 | 3158篇 |
内科学 | 6161篇 |
皮肤病学 | 4001篇 |
神经病学 | 2040篇 |
特种医学 | 484篇 |
外国民族医学 | 4篇 |
外科学 | 3042篇 |
综合类 | 3764篇 |
现状与发展 | 7篇 |
预防医学 | 1559篇 |
眼科学 | 814篇 |
药学 | 4006篇 |
17篇 | |
中国医学 | 1630篇 |
肿瘤学 | 674篇 |
出版年
2024年 | 124篇 |
2023年 | 770篇 |
2022年 | 1298篇 |
2021年 | 1802篇 |
2020年 | 1636篇 |
2019年 | 1584篇 |
2018年 | 1582篇 |
2017年 | 1656篇 |
2016年 | 1702篇 |
2015年 | 1691篇 |
2014年 | 2289篇 |
2013年 | 3472篇 |
2012年 | 1934篇 |
2011年 | 2086篇 |
2010年 | 1731篇 |
2009年 | 1735篇 |
2008年 | 1687篇 |
2007年 | 1654篇 |
2006年 | 1426篇 |
2005年 | 1239篇 |
2004年 | 1104篇 |
2003年 | 895篇 |
2002年 | 791篇 |
2001年 | 698篇 |
2000年 | 489篇 |
1999年 | 578篇 |
1998年 | 555篇 |
1997年 | 460篇 |
1996年 | 459篇 |
1995年 | 407篇 |
1994年 | 342篇 |
1993年 | 338篇 |
1992年 | 286篇 |
1991年 | 258篇 |
1990年 | 216篇 |
1989年 | 235篇 |
1988年 | 201篇 |
1987年 | 95篇 |
1986年 | 89篇 |
1985年 | 114篇 |
1984年 | 98篇 |
1983年 | 76篇 |
1982年 | 53篇 |
1981年 | 46篇 |
1980年 | 38篇 |
1979年 | 31篇 |
1978年 | 23篇 |
1977年 | 18篇 |
1976年 | 24篇 |
1975年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
Eros S. Chaves Robert C. Wood Archie A. Jones Dewey A. Newbold Mary A. Manwell Kenneth S. Kornman 《Journal of clinical periodontology》1993,20(2):139-143
Abstract Bleeding on probing (BOP) and the gingival index have been used to clinically characterize the degree of gingival inflammation. It is, however, unclear to what extent these parameters correlate to each other and to probing pocket depth (PD). The purpose of this clinical study was to evaluate the association between BOP and GI bleeding (scores of 2 and 3), as well as the relationship of these variables to PD, in a group of patients presenting with naturally-occurring gingivitis. Based on screening examinations of 125 subjects with at least 20 teeth, no more than 4 sites with PD over 6 mm, a BOP frequency of 30% or greater, and no systemic condition that would influence the inflammatory response, were selected. 2 weeks after screening they were examined at 6 sites per tooth for plaque index, GI, PD and BOP. A standardized pressure sensitive probe (Florida Probe) with 20 g probing force was used for BOP and PD measurements. In this population, means of 40.9% (S.E.= 1.36) BOP sites and 35.3% (S.E, = 1.81) GI bleeding sites per patient were found. A total of 20,008 sites ranging in PD up to 5.9 mm were evaluated; however, the majority of sites (19,723, 98.6%) presented with <4 mm PD. When sites were evaluated, BOP demonstrated a positive correlation with PD, whereas GI bleeding correlated with PH. For sites characterized by the absence of BOP as well as the absence of GI bleeding (scores 0 and 1), the highest % of agreement between the 2 indices (77.7%) was found in shallow sites (0.1–2 mm). In contrast, when sites presenting with both BOP and GI bleeding were analyzed, the highest % of agreement (85,4%) was found for sites with PD >4.0 mm. In this gingivitis population group, it appears that BOP and GI bleeding evaluate distinct inflammatory1 conditions of the gingival tissues, and the relationship between the 2 clinical parameters may vary according to PD at the individual site examined. 相似文献
33.
34.
F. Estelle R. Simons on Behalf of the Early Prevention of Asthma in Atopic Children Study Group 《Pediatric allergy and immunology》2007,18(6):535-542
There are more than 40 H(1)-antihistamines available worldwide. Most of these medications have never been optimally studied in prospective, randomized, double-masked, placebo-controlled trials in children. The aim was to perform a long-term study of levocetirizine safety in young atopic children. In the randomized, double-masked Early Prevention of Asthma in Atopic Children Study, 510 atopic children who were age 12-24 months at entry received either levocetirizine 0.125 mg/kg or placebo twice daily for 18 months. Safety was assessed by: reporting of adverse events, numbers of children discontinuing the study because of adverse events, height and body mass measurements, assessment of developmental milestones, and hematology and biochemistry tests. The population evaluated for safety consisted of 255 children given levocetirizine and 255 children given placebo. The treatment groups were similar demographically, and with regard to number of children with: one or more adverse events (levocetirizine, 96.9%; placebo, 95.7%); serious adverse events (levocetirizine, 12.2%; placebo, 14.5%); medication-attributed adverse events (levocetirizine, 5.1%; placebo, 6.3%); and adverse events that led to permanent discontinuation of study medication (levocetirizine, 2.0%; placebo, 1.2%). The most frequent adverse events related to: upper respiratory tract infections, transient gastroenteritis symptoms, or exacerbations of allergic diseases. There were no significant differences between the treatment groups in height, mass, attainment of developmental milestones, and hematology and biochemistry tests. The long-term safety of levocetirizine has been confirmed in young atopic children. 相似文献
35.
36.
37.
F. Njaa T. Baekken D. Bjaamer J. I. Holme F. Korsrud O. Woxen A. K. Olsen 《Pediatric allergy and immunology》1992,3(1):39-42
Fifty–five children 6–16 years old with allergic rhinoconjunctivitis due to both birch and grass pollinosis were randomized into 2 parallel groups, treated in double–blind fashion with either levocabastinc (LEV) eye–drops twice daily plus placebo eyedrops twice daily or sodium cromoglycate (SCG) eyedrops 4 times daily for 3 months. Spersallerg® (antazolini chloride + tetryzolini chloride) eyedrops were allowed as rescue medicine. All children received basic treatment with an antihistamine (terfenadine) during the complete trial period, and a local nasal corticosteroid if needed. Eye symptoms were recorded daily by the patients and at 4 visits by the investigator, at start and after 4, 10 and 13 weeks. Pollen counts were performed and a blood sample was collected at start and end of the treatment. The global evaluation of treatment was similar for the 2 groups, and there was no significant difference in any effect parameter except for the symptom, itchy eyes, which had lower score in the SCG group as evaluated by the investigator after 4 weeks. On days with low pollen counts the patients in the SCG group had fewer days with moderate or severe eye symptoms. It is concluded that even though LEV and SCG eyedrops were given in addition to systemic treatment with an antihistamine, no consistently significant differences in clinical effect were found between the 2 treatment groups, but the SCG group experienced slightly less eye symptoms throughout the trial. LEV eye–drops appear safe in long–term treatment in children, and no signs of tachyphylaxis were recorded. 相似文献
38.
39.
n. holmén † s. isaksson † m. simrén h. sjövall & l. öhman † 《Neurogastroenterology and motility》2007,19(2):119-125
40.